

Collage of cases and brief review of the laboratory diagnosis and molecular testing in autoimmune haemolytic anaemia

Harkiran Arora¹, Shalini Trivedi², Pooja Jain², Udita Singhal², Arunpreet Kaur³, Aditi Raina⁴

¹Department of Blood Bank and Transfusion Medicinet Attending Consultant, FMRI, Gurgaon, Haryana, India, ²Department of Pathology, E.S.I.C. Hospital and Dental College, Rohini, Sector-15A, New Delhi, India, ³Department of Blood Bank and Transfusion Medicine, AIIMS, Raebarelli, Uttar Pradesh, India, ⁴Department of Pathology, Saraswati Institute of Medical Sciences, Hapur, Uttar Pradesh, India

Abstract

Autoimmune haemolytic anaemia (AIHA) is an acquired heterogenous clinical entity with variable presentations like acute haemolysis or mild, chronic haemolysis compounded with acute exacerbation in winters or fatal uncompensated haemolysis. A step-wise approach to the diagnosis and characterisation of AIHA should be undertaken, firstly the diagnosis of haemolysis followed by the establishment of immune nature with the aid of direct agglutination tests (DAT). Simultaneously the other causes of immune haemolysis need to be excluded too. In light of advancements in diagnostics, a wide array of investigations can be used like absolute reticulocyte count, bone marrow responsiveness index to establish the evidence of haemolysis, sensitive gel technology, enhanced DAT assays, e.g., modified DAT with low ionic strength saline solution (LISS) at 4°C, DAT assays utilizing reagents such as anti-IgA and anti-IgM and DAT by flowcytometry, to detect RBC bound autoantibodies (Abs) and monospecific DAT to establish immune causes of haemolysis and characterisation of the autoantibodies. The compensatory role of bone marrow and synchronous pathologies like clonal lymphoproliferation, dyserythropoiesis, fibrosis are important factors in the evolution of the disease and aid in the customisation of treatment modalities. The laboratory work up should aim to diagnose underlying diseases like chronic lymphoproliferative disorders, autoimmune disorders and infectious diseases. Also, tests like autoimmune lymphoproliferative syndromes (ALPS) screening panel and Next-generation sequencing (NGS) panel for RBC membrane disorders, RBC enzymopathies, and congenital dyserythropoietic aneamia have found their place. It is incumbent upon the clinicians to use the all-available diagnostic modalities for the accurate diagnosis, prognostication and customisation of the therapy.

Keywords: Direct antiglobulin test, enhanced DAT, warm autoimmune haemolytic anaemia cold agglutinin syndrome

Introduction

Autoimmune haemolytic anaemia (AIHA) is a heterogeneous disease with myriad presentations from mild/compensated

Address for correspondence: Dr. Shalini Trivedi, Pathology Laboratory, E.S.I.C. Hospital and Dental College, Rohini, G-235, First Floor, Vikas Puri, New Delhi - 110018, India. E-mail: shalinitrivedi031@gmail.com

Received: 01-11-2022 **Accepted:** 17-04-2023 **Revised:** 10-04-2023 **Published:** 06-03-2024

Acce	ess this article online
Quick Response Code:	Website: http://journals.lww.com/JFMPC
	DOI: 10.4103/jfmpc.jfmpc_2131_22

disease to severe disease which can be life-threatening.^[1] Immune haemolysis is mediated through the Abs directed against antigens on the erythrocyte membrane with/without complement fixation.^[1,2] Immune haemolysis triggers compensatory responses like increased erythropoietin levels leading to compensatory marrow hyperplasia. The landscape of AIHA has evolved over the years; today apart from conventional therapies like steroids, immunosuppressants, and splenectomy, the calibrated use of bone marrow stimulating agents/immunomodulating agents

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Arora H, Trivedi S, Jain P, Singhal U, Kaur A, Raina A. Collage of cases and brief review of the laboratory diagnosis and molecular testing in autoimmune haemolytic anaemia. J Family Med Prim Care 2024;13:409-16.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

are being practised in the diverse settings of clinical trials and routine clinical practice.^[1] The knowledge of the pathogenesis of AIHA has grown manifold, beyond the role of Abs, complement, and antibody-dependent cell-mediated cytotoxicity. The body of evidence regarding pathogenesis implicates decreased CD4+ T-regs, imbalance of T-helper 1/2 cytokines, and amplified activity of immune-competent cells like cytotoxic CD8+ T lymphocytes, macrophages and natural killer cells.^[1] The compensatory roles of bone marrow and synchronous pathologies like clonal lymphoproliferation, dyserythropoiesis, and fibrosis are important variables recognized in the evolution of the disease and the customization of treatment modalities on a case-to-case basis.^[1,3,4]

AIHAs are classified as primary or secondary. The secondary AIHAs occur in the settings of lymphoproliferative disorders, solid tumours, immunodeficiencies, transplants, autoimmune conditions, various infectious diseases, and drugs in which various immunologic mechanisms are implicated.^[1] AIHAs are also classified as warm (75% of all the cases), cold (15% of all the cases), and mixed (< 5% of the cases) based on the thermal amplitude of the implicated auto Abs.^[5] The systematic review by Hill et al.[6] conducted in 2019 deduced that there is ambiguity in the definitions and diagnostic criteria of AIHA used by various researchers. In the majority of the studies the Direct Antiglobulin test (DAT) positivity was deemed essential for the diagnosis of AIHA. The entities exhibiting immune haemolysis with DAT positivity like delayed haemolytic transfusion reaction (DHTR), haemolytic disease of the newborn (HDFN) especially in paediatric population drug-induced immune haemolysis, alloimmune haemolysis secondary to solid organ/hemopoietic stem transplantation have to be excluded too, to establish the diagnosis of AIHA.^[6] However, the DAT positive report should also be viewed with caution, as DAT positive results can be associated with other pathologies, like passive deposition of immune complexes or Abs on RBCs in hepatic disease, malignancy, autoimmune disorders like systemic lupus erythematosus, renal diseases, secondary to drug therapies with IV Immunoglobulin (IV Ig), antithymocyte globulin. In absence of these causes, diagnosis of AIHA can be rendered without a doubt.[6,7]

Also, there is an inherent lacuna in this definition of AIHA as it overlooks DAT-negative AIHA.^[7] AIHA affects both the paediatric and adult populations, the estimated annual incidence in the paediatric population is approximately 0.8 per 100,000 individuals under 18 years old which is lower than in the adult population.^[7]

Case 1: Secondary Warm Autoimmune Haemolytic Anaemia (WAIHA) with Chronic Lymphoproliferative Disorder (CLPD)

We present a case of a 62-year-old male, diagnosed as a case of mantle cell lymphoma, presented with anaemia with

haemoglobin (Hb): 7.2 gm/dl [12.0–15.5]), total leucocyte count: 18×10^{9} /L (3.7–9.7 × 10⁹/L) total platelet count (TPC): 100×10^{9} /L, (179–373 × 10⁹/L), Lactate dehydrogenase (LDH): 344 U/L [122-222]), peripheral smear showed macrocytic picture with polychromasia, leucocytosis, and 15% lymphoma cells, normoblastaemia. In flow cytometry, lymphoma cells expressed CD19, CD20, FMC-7, CD5, and Cyclin D1, but lacked expression of CD23 and CD10.

The air-dried, giemsa-stained smears of aspirate of the right cervical lymph node showed a monotonous population of small intermediate-sized sized lymphoid cells with an enlarged, nucleus with an irregular nuclear outline coarse chromatin, scant cytoplasm, and absence of large or "transformed" lymphoid cells.

The excision biopsy lymph node specimen measuring $3.5 \text{ cm} \times 3.0 \text{ cm}$ and on gross examination showed a homogenous tan cut surface. On microscopic examination, it showed diffuse effacement of the nodal architecture with the presence of small to medium-sized monomorphic cells with an irregular nuclear outline, clumped chromatin, and single micro to inconspicuous nucleoli. [Figure 1a, b]

Bone marrow and bone marrow biopsy showed nodular and paratrabecular arrangement of small to medium-sized monomorphic lymphoid cells with irregular nuclear borders, clumped chromatin, and inconspicuous nucleoli. On immunohistochemistry, lymphoma cells expressed CD20, CD5, and Cyclin D-1. The blood sample received for blood typing was typed as B Rh-positive with 1+ positive auto control at room temperature (RT), 3+ positive at 37°C/Coombs phase and negative at 4ºC (by conventional tube technique). Polyspecific DAT (IgG + C3d) showed 3+ positivity and monospecific DAT positive 3+ with IgG and C3d both. IAT was 2+ positive (DAT and IAT by column agglutination technique). Antibody screening (AS) (BIO RAD Diamed) with three cell panels and antibody identification (AI) (BIO RAD Diamed) with 11 cell panels showed pan agglutination of uniform strength 2+ at 37ºC (in Coomb s phase). The packed red blood cell concentrate



Figure 1: Micrograph of histology, (a) and cytology (b) of MCL. (a) H and E stained slide of mantle cell lymphoma, lymph node biopsy (10×10). Showing diffuse effacement of the nodal architecture with the presence of small to medium-sized monomorphic cells. (b) H and E stained slide of Mantle Cell Lymphoma, Lymph Node Biopsy (40×10). Showing diffuse effacement of the nodal architecture with the presence of small to medium-sized monomorphic cells with an irregular nuclear outline, clumped chromatin, and single micro to inconspicuous nucleoli

(PRBC) transfusion was withheld in line with restrictive transfusion strategies based on AABB guidelines, as the patient was hemodynamically stable. However, erythrocyte transfusions should be considered in anaemic patients with cardiopulmonary symptoms regardless of the Hb levels. In such patients, special compatibility procedures are mandated to rule out the presence of a coexisting allo Ab. The auto Abs are also directed against major erythrocyte antigens, e.g., Rh, Rh-related antigens, Band 3, and glycophorin; hence, Rh negative PRBC units are preferred. The compatibility test should include the removal of auto abs from the patient's serum by auto adsorption with either autologous RBCs or with selected panels of RBCs with known antigen phenotype leaving behind/unmasking the coexistent allo Ab if present This is followed by AS with RBC panels with known RBC antigenic expression on an adsorbed serum to look for allo Ab. Lastly the crossmatch is done to identify compatible units. In cases with severe anaemia, the availability of autologous erythrocytes maybe not be enough to perform an autologous adsorption test.^[8] Another option that can be used is the transfusion of phenotypically matched PRBC to the patient, which requires the determination of the antigen profile of the patient's erythrocytes using typing sera, providing options for safe transfusions.^[8]

Case 2: Primary Mixed AIHA with Broad Thermal Amplitude Abs

A 22-year-old female patient presented with gradual onset of fatigue, with a history of abrupt fall of haemoglobin over the duration of one month preceded by fever for one day with arthralgias without joint effusion, before and after the onset of fever. The patient had significant negative histories of pregnancy and drug intake. Laboratory test results with reference range provided in brackets) were significant for Hb (ranging from 6.7 to 5.6 gm/dL [12.0–15.0]), MCV; 104.0fl [78.5-96.4]), absolute reticulocyte count: 145 X 109/L [40.6-111.8], LDH; 1049 U/L [122-222]), total bilirubin (4.02 mg/dL [0.1-1], indirect bilirubin: 3.39 mg/dl), and blood smear showing polychromasia. The blood sample was received for blood group typing. The case showed naked eye RBC agglutination with a discrepancy in forward and Reverse Blood Grouping at room temperature. So fresh patient EDTA sample was collected under warm conditions. The RBC and Serum were separated immediately by centrifugation at 3000 rpm for 3 min. The cells were washed 3 times with warm normal saline at 37°C. Forward and reverse blood grouping was done at 4°C, room temp and 37° C by tube method which showed discrepant results at 4º C and room temp. However, at 37°C, blood Group was confirmed as A RhD positive. Autocontrol was positive at 4°C, room temp and 37°C/Coombs phase suggesting the presence of auto Ab. [Table 1] Polyspecific DAT (IgG + C3d) showed 4+ positive (Column Agglutination), Monospecific DAT positive (4+) for IgG, IgM, C3d (Column Agglutination). AS (BIO RAD Diamed) with three cell panel and AI (BIO RAD Diamed) with 11 cell panel showed pan agglutination of uniform strength 2+ at 37°C (in Coomb s phase) and at 4°C (in saline phase). IgM antibody titre done by double dilution tube method in saline phase at 4°C was 16. Both warm (IgG) and cold (IgM) autoantibodies with high thermal amplitude were found in this case, so suggestive of mixed AIHA.

The patient was started on prednisolone therapy of 60 mg daily for 4 weeks along with folate supplementation till haemoglobin reached 12 gm/dl; thereafter, the dose of prednisolone was tapered by 20 mg every week until a dose of 20 mg daily was reached, followed by staggered tapering over 8 weeks. Subsequently, the patient was followed up for trends of C-reactive protein, LFT, Hb, and Reticulocyte Count [Graph 1].

The patient attained a complete response within 3 months and was followed for one year with no evidence of relapse.^[8]

Case 3: Cold AIHA Secondary to Viral Infection

We report a case of a 42-year-old Indian male patient presenting with dyspnoea, recent onset of fatigue, symptoms of cold intolerance, and acrocyanosis. The blood sample received for hemogram revealed significant anaemia with Hb: ranging from 6.7 to 5.6 gm/dl [13.3–17.2 gm/dl]), MCV; 130.0*** fl [81.2-94.0]), mean corpuscular haemoglobin (MCH):***pg (27.1-32.5), mean corpuscular haemoglobin concentration (MCHC):***(32.5–36.7 g/dL), MCV, MCH & MCHC were flagged by the counter, corrected leucocyte count: 9.96 × 10⁹/L (3.7–9.7 × 10⁹/L), TPC: 130 × 10⁹/L (179–373 × 10⁹/L), absolute reticulocyte count (119 × 10⁹/L [55.1–



Graph 1: Graphical representation of laboratory parameters pre and post treatment with steroids

	Table 1: Discussion of blood grouping at different temperature conditions									
Temp		Fo	rward groupin	g	Reverse grouping					
٥C	Anti A	Anti B	Anti D1	Anti D2	NS	A cell	B cell	O cell	AC	
4 °C	3+	3+	3+	3+	3+	2+	3+	2+	2+	invalid
RT	3+	3+	3+	3+	3+	2+	3+	2+	2+	invalid
37°C	3+	negative	3+	3+	weak	negative	3+	negative	weak	A+

140.7 X10⁹/L]), LDH (1049 U/L [122-222]), total bilirubin (4.02 mg/dL [0.1-1]), indirect bil (3.39 mg/dl), and blood smear showing polychromasia. The peripheral smear examination showed marked erythrocyte agglutination, polychromasia, and five nucleated red blood cells (nrbcs)/100 wbcs counted. [Figure 2] The absence of abnormal/premature cells of lymphoid/myeloid cells was remarkable. The flagging of MCV, MCHC, and MCH is in line with the findings of erythrocyte agglutination. Consequently, the sample was received for blood group typing, DAT, and cross matching for transfusion. Autoagglutination was present in the sample at RT. Fresh sample was collected in the EDTA vial and incubated at 37°C for half an hour. Cell washing was done 5-6 times with warm saline at 37°C C. In this way, serum and cell grouping was performed and the blood group came out to be AB positive. Autocontrol by conventional tube technique at 4°C was positive but negative at 37°C/coombs phase. We performed cold agglutinin titres which came out to be 1024. The monospecific DAT (column agglutination) was positive for C3d, and negative for IgG. The PCR test for mycoplasma pneumonia, cytomegalovirusm and Epstein Barr virus were negative. Serum complement C3 and C4 levels were reduced. Serum protein immunofixation was positive for IgM; bone marrow aspiration and bone marrow biopsy were unremarkable effectively ruling out the presence of a lymphoproliferative process. The patient attained remission with four doses of rituximab and improved on clinical and laboratory parameters.^[8]

Case 4. Case of Idiopathic WAIHA

A 42-year-old Indian male presented with recent onset of fatigue to the medical OPD. Physical examination showed marked pallor, dyspnoea on rest, and hepatomegaly. Laboratory results (with reference ranges provided in brackets) were significant for haemoglobin (Hb):5.9 g/dL [13.3–17.2 gm/dl], mean cell volume (MCV; 107.0 fl [81.2–94.0 fl]), absolute reticulocyte count (175 X10⁹/L [55.1–140.7 × 10⁹/L]), total platelet count: 194×10^9 /L, (179–373 × 10⁹/L), LDH 260 U/L [122–222]), total bilirubin (1.2 mg/dL [0.1–1]), and blood smear showing macrocytic picture with presence of spherocytes, polychromasia 2 nrbcs/100 was counted. [Figure 3] The patient was typed as A Rh-positive. Since the patient had symptomatic anaemia with an urgent requirement for transfusion, and crossmatching was performed with several random A positive and O positive packed red cells, but no compatible unit was detected. So detailed workup was done. Autocontrol (conventional tube technique) at 37°C/coombs phase found to be positive and negative at room temperature and at 4°C. Polyspecific DAT (IgG + C3d) by Diamed Bio Rad Gel Technique was found to be positive. Monospecific DAT was positive for IgG and C3d. He received two 'least incompatible' A Rh-positive non-leuco reduced packed red cell units over the period of two days after informed consent. The transfusions were closely monitored clinically and by laboratory parameters.^[9]

Case 5: WAIHA Secondary to Hodgkin's Lymphoma with Congestive Heart Failure

A 16-year-old male presented to the emergency room with gradual onset of fatigue and shortness of breath at rest. Physical examination showed marked pallor, right cervical lymphadenopathy, and raised jugular venous pressure. There is significant negative history of transfusions, and ingestion of unknown drugs. Laboratory results (with reference ranges provided in brackets) were significant for Hb: 1.9 g/dL ([11.0–14.3]), MCV: 92.0 fl ([80.8–86.6]), absolute reticulocyte count (ARC):119 \times 10⁹/L ([39.0–100.0]), LDH: 260 U/L ([122-222]), total bilirubin: 1.2 mg/dL [0.1-1], and blood smear showing polychromasia. The patient was typed as A Rh-negative with auto abs, DAT showed 2+ positive by tube, and direct antiglobulin test with poly-specific Coomb's reagent (IgG + C3d) was positive. The patient showed pan reactive AS with all three reagent cells Indirect Antiglobulin test (IAT) with warm thermal amplitude of these antibodies. In view of life-threatening anaemia with features of chronic heart failure, with an urgent requirement for transfusion, detailed phenotyping was not done and crossmatching was performed with several random A Rh-negative packed red cell, but no compatible unit was detected. He received three 'least incompatible' A Rh-negative non-leuco reduced packed red cell units over three



Figure 2: Leishman stained slide (10×10) . Micrograph showing RBC agglutination in peripheral smear



Figure 3: Leishman stained slide (10 \times 10). Micrograph showing spherocytes on peripheral smear

days after informed consent. The transfusions were eventless and an adequate increase in Hb was reported. Besides, he was also started on diuretics, but steroids were withheld as investigations like fine needle aspiration cytology (FNAC) and excision biopsy were pending. On day 3, post-FNAC and excision biopsy were performed. On examination, 4 cm × 3 cm matted lymph nodes with rubbery feel were palpated. The steroid therapy was initiated, and the patient was followed up by the increasing trend of ARC.^[10] The giemsa stained FNAC smears show polymorphous population of eosinophils, plasma cells, and histiocytes with the presence of mononuclear and bi nucleate cells with prominent eosinophilic nucleoli with ample amphophilic cytoplasm. The excision biopsy showed H&E-stained sections with enlarged lymph with total effacement of lymphoid architecture, presence of polymorphous population of eosinophils, plasma cells, and histiocytes with the presence of mononuclear and bi nucleate cells with prominent nucleoli with ample cytoplasm consistent with Reed-Sternberg cells and mononuclear variants. [Figure 4] Immunostains positively stained abnormal cells for CD15 and CD 30 and negatively for CD20, CD45, and CD3.

Micrograph showing total effacement of lymphoid architecture, presence of polymorphous population of eosinophils, plasma cells, and histiocytes with the presence of mononuclear and bi nucleate cells with prominent nucleoli with ample cytoplasm consistent with Reed–Sternberg cells and mononuclear variants

Discussion

Clinical presentation: The classical presentation in WAIHA is insidiously developing anaemia with clinical symptoms like fatigue, weakness, dyspnoea on exertion, and dizziness with association with less frequent symptoms like bleeding, fever, cough, and symptoms related to aetiology.^[9] Whereas patients with cold AIHA (primary/secondary) show chronic disease with symptoms like fatigue and pallor, punctuated with acute exacerbations during cold weather. The symptoms during acute



Figure 4: H and E stained slide of mantle cell lymphoma, lymph node biopsy (40×10)

exacerbation include Raynaud's phenomenon, acrocyanosis, and features of acute haemolysis, e.g., haemoglobinuria and haemoglobinemia secondary to cold exposure.^[9]

Patients with mixed-type AIHA also have a chronic presentation with intermittent severe exacerbations without temporal association with cold exposure, and accompanying acrocyanosis and Raynaud's phenomenon.^[9]

The basic and advanced laboratory, serological, molecular and radiological investigations to be carried out in suspected AIHA patients to arrive at a diagnosis, characterisation of the disease, ruling out other causes of immune haemolysis, investigate for secondary/associated disorders or diseases, and for the prognostication and titration of the treatment are discussed in detail [Tables 2 and 3]

A significantly increased LDH and RBC fragments on peripheral smear, along with the presence of urinary hemosiderin are indicators of an intravascular haemolytic process.^[7]

DAT negative AIHA

The causes of DAT-negative AIHA are enumerated in the decreasing order of prevalence:

- Red blood cell-bound IgG molecules, below the threshold of detection of the DAT, in the event of ongoing *in vivo* haemolysis
- Low-affinity IgG Abs which may be washed off the red cells during the washing phase, hence missed on conventional DAT.
- IgA auto Abs or rarely monomeric IgM not detected by conventional DAT.^[9,11]

To increase the sensitivity of diagnosis of AIHA, following modifications of DAT are available. e.g., micro-column (gel), solid-phase, polybrene, flow cytometry methods, as well as enzyme-linked antiglobulin, immunoradiometric, and mitogen-stimulated tests.^[11]

The modified technique of washing red cells with cold saline or LISS may be effective in detecting low-affinity antibodies because low-affinity Abs is eluted during the washing step in the conventional tube technique.^[11] The sequence of investigations required for the diagnosis of DAT-negative AIHA is discussed in flowchart shown in Figure 5.

Reticulocytes in AIHA

In HA cases associated with iron/Vitamin B12 deficiency, infections, or autoimmune conditions, the compensatory reticulocytosis response can be deficient or absent. The association of reticulocytopenia with AIHA was observed in 39% of paediatric cases and about 20% of adult cases, despite erythroid hyperplasia in the marrow. This finding can be attributed to immune attacks on late-stage erythroid precursors or due to delayed bone marrow response.^[7,12,13] The reticulocytopenia

Laboratory and Kadological Investigations required Remark&** Complex Blood Courts with Henoglobin (Hb), RDC court Hb: Decreased Mean Corpuscular Volume (ACV): N/Increased. Normocycit/Alexcorptic pricerue. Rardy thrombucy treema: Invest Syndrome (ES) in the Pediatric population. Increased. Plasma HB Reticulory to court and other miculoryte indices Reticuloryte court (AIG), and bone marrow responsiveness index (BMR) are used. Reticuloryte court and other miculoryte indices Reticuloryte court (AIG), and bone marrow responsiveness index (BMR) are used. Pripheral smear coamination Increased. Reticuloryte court (AIG), and bone marrow responsiveness index (BMR) are used. Secure bilinition and liver function tests (LFT) Normal/Increased. Normal/Increased. Secure bilinition and liver function tests (LFT) Normal/Increased. Normal/Increased. Secure bilinition and liver function tests (LFT) Normal/Increased. Normal/Increased. Varian for the considerin Provinces in active display for province. Normal/Increased. Varian for the mosiderin Provinces in active display for province. Normal/Increased. Varian for the mosiderin Provinces in active display for province. Normal/Increased. Varian for the	Table 2. Dasie and advanced laboratory	
Complexe Biood Court with Hemoglobin (Hb), RBC court His: Decreased & RRC indices: Non-corps://Macroscipic.picture. Rand, Homooytepini: Eventses Rest (Molece) Plama Hb Rest-coloryte picture. Raticulacytic count and other reticulocyte indices Rest-coloryte picture. Rest-coloryte court. A(KC), MCC, and Done marrow responsiveness index (BMR) are used. Rest-coloryte court. A(KC), and Done marrow responsiveness index (BMR) are used. Peripheral sincer examination Rest-coloryte picture with micro spherocytes in w AHLAY-BC Rest-coloryte picture with micro spherocytes in w AHLAY-BC Rest-coloryte picture with micro spherocytes in w AHLAY-BC Serum bilinibia and liver function tests (LFT) Normal / increased Serum hectuae dulydrogenuse enzyme (LDH) Normal / increased This rest of miles in neare of miles hecmolysis History discust and the paper discust to a spheroscient in tests (GCH). Line routine examination Line rest of miles interased in hepptic discust to a spheroscient in tests of miles interased in hepptic discust to a spheroscient in tests (GCH). Line routine examination Line rest of mines being discuster to a spheroscient in tests of miles interased in hepptic discust to a spheroscient in the paper discust to a spheroscient in tests of mines being discuster to a spheroscient in tests of mines being discuster to a spheroscient in tests of mines being discuster to a spheroscient in tests of mines being discuster to a spheroscient in tests of mines berespheroscient in tests of tests of mines bernstable in a	Laboratory and Radiological Investigations required	Kemark ^{1,6,7]}
86 RRC mitnes. Mem Corpuscibr Volume (MCX): N/Increased. Pisma IIb Normocycit. Rask yludome (US) in the Pediatric population. Raticulacyte count and other reticulocyte indices Raticulacyte count of MRQ. Raticulacyte count and other reticulocyte indices Raticulacyte count of MRQ. Perpheral smare examination Raticulacyte count (ARQ), and bone marrow responsiveness index (BMRI) are used. Perpheral smare examination Increased polychromatophils for age. Perpheral smare examination Increased polychromatophils for age. Normal: in cases of midler haemolysis. Normal: in cases of midler haemolysis. Strum blindbin and lever function tests (LPT) Normal: in cases of midler haemolysis. Normal: in cases of midler haemolysis. Increased. Prepheral smare examination Decreased. View of themosterin (First samped) Prepheral retal delydogenase enzyme (LDH) Increased. Prepheral retal abstrate delydogenase enzyme (LDH) Prepheral smare esamination Urine routine examination Decreased. Prepheral Feel substes If Ess supperted. Serum hemogenia and blood vera mitrogen (RUN) If Ess is supperted. Serum netwopexing and blood vera mitrogen substep in the count of mider haemolysis. If Ess supperted. Perpheral retal substep in the substep in the substrate antigen substep in themostep in the substep in them	Complete Blood Count with Hemoglobin (Hb), RBC count	Hb: Decreased
Plasm HB Rardy thorbics/uponic plasmic Raice Monoscreptonic Lionas Syndrome (LS) in the Pediatic population. Increased Reticulocytoxis is a common finding. Absolute reticulocyto court (AG), and bore marrow responsiveness index (BMRI) are used. Peripheral smear examination Reticulocytoxis in a Common finding. Absolute reticulocyto court (AG), and bore marrow responsiveness index (BMRI) are used. Peripheral smear examination Increased polychromatophils for age. Normocytic/Macroscytic picture with micro spherocytes in w MILA*(RC) agglutinis and molecus in consets and molecus in consets econdary to bone marrow infiltration, by hyphylproliferative disorder or Parvovins BP and edit fingments/ teardrop cell (suggettive of bone marrow infiltration). Persipheral smear examination Normal/Increased. Serum bilinabin and lever function tests (LFT) Normal/Increased. *Normal in cases of milder heamolysis. UFF Specifically in infants to rule out AHIA with ginnt cell beparitis (GCH). Increased. Serum hemopesin and hapoglobin Descreased. * Unare south cases of milder heamolysis. UFF Specifically contant BLGs and heamolybis. UFF specifically contant BLGs and heamolybis. Increased unoblino. Increased unoblino. Evidence of unary BLGs and heamolybis. Uranes of unary BLGs and heamolybis. Uranes of unary BLGs and heamolybis. Uranes of unary BLGs and heamolybis. Evidence of unary BLGs and heamolybis. Indexed if CLG southers The Specifically in technage females. Indicated Hyperipheral sense south and loper-specific south and loper-specific south and ore nearow aspinonia if JBM Abs aredecectod. <	& RBC indices.	Mean Corpuscular Volume (MCV): N/Increased.
Plasma Hb Increased. Reticulosyte count and other reticulosyte indices Reticulosyte count of the Values Jopannon. Reticulosyte count and other reticulosyte indices Reticulosyte count (ARC), and bone marrow responsiveness index (BMRM) are used. Reticulosyte count (ARC), and bone marrow responsiveness index (BMRM) are used. Reticulosyte count (ARC), and bone marrow responsiveness index (BMRM) are used. Peripheral smear examination Increased jopk/monatophile arise does are used. Serum blinubin and lever function tests (JFT) Normozyte/Marcyce joptima roll agglutnin synthome (CAS)/red cell fugments/ transforg/cells/aggetors to value out AHIA with giant cell hepatitis (GCT). Serum blinubin and lever function tests (JFT) Normozyte/Marcyce joptima roll agglutnin synthome (CAS)/red cell fugments/ transforg/cells/aggetors to value out AHIA with giant cell hepatitis (GCT). Serum blinubin and laptoglobin Decreased. *UDT for a bin remased in hepatic disease too. Urin routine examination Livid-need of unarray hemoiderin after a week. *UDT for a bin systemated unbilation after a week. Urin routine examination If ES is suspected. *UDT for a bin systemated unbilation after a week. Urin routine examination If ES is suspected. *UDT for a bin for a bin remased in hepatic disease too. Serum returnine ad bod ure an intregen (BUN) If ES is suspected.		Normocytic/ Macrocytic picture. Rarely thrombocytopenia: Evans Syndrome (ES) in the Pediatric population
Internation Provide of the set of the	Plasma Hh	Increased
Reticulary to contrained relationsly is contract. Reticulary to contract (ARG), and hone marrow responsiveness index (IbMR) are used. Reticulary to contract (ARG), and hone marrow responsiveness index (IbMR) are used. Reticulary to contract (ARG), and hone marrow responsiveness index (IbMR) are used. Peripheral smear examination Increased poly-thoroutophile rative disorder or Pervovinus BPI infection. Peripheral smear examination Increased poly-thoroutophile rative disorder or Pervovinus BPI infection. Secum bilinabin and liver function tests (LTT) Increased poly-thoroutophile rative disorder or Pervovinus BPI infection. Secum bilinabin and liver function tests (LTT) Normal, Increased of hone marrow infinition). Presence of radicated RBCs Normal, Increased of hone marrow infinition). Secum bilinabin and liver function tests (LTT) Normal, Increased of hone marrow infinition. Secum hemopexin and haptoglobin The Specifically in infinition ratio receased in hepatic disease too. Unite rotatic examination Treased in hepatic disease too. Unite rotatic examination Evidence of uninary RECs and haemoglobin. Unite rotatic examination Freidence of uninary themosiderin after a week. Peripheral T-cell subsets If ES is suspected. Secum instructiopedulinis and decarophonesis with antiogen antigen, anti, 3 Specineremales. Se	Reticulocyte count and other reticulocyte indices	Reficulocyte count>2%
Absoluter refeatoryte count (ABC), and bone marrow responsiveness index (BMRI) are used Peripheral smear examination Reliciplicitytopenii in AIIIA cm be present in cares secondary to bone marrow infiltration by brophopolificative disorder or Parvoirus B19 infection. Peripheral smear examination Increased polebriomatophils for age Normacy/Discret/Alerccycle priorus with inition opheropytes in w AIIIA//RUC agglitrinites and rouleaux in cold agglitrinites opheropytes in w AIIIA//RUC agglitrinites and rouleaux in cold agglitrinites opheropytes in w AIIIA//RUC agglitrinites and rouleaux in cold agglitrinites opheropytes in w AIIIA//RUC agglitrinites and rouleaux in cold agglitrinites and rouleaux in the partic disease too. Serum hacked delydogenase enzyme (DDI) Increased in hepatic disease too. Urine courtine examination Evidence of uniany PROS and haemoglobin. Urine for hemosiderin Evidence of uniany PROS and haemoglobin. Urine routine examination Evidence of uniany PROS and haemoglobin. Serum instruction discretectuber antity antice agglitrinite and routing disorders <	Refeatocyte count and other refeatocyte indices	Reticulocytosis is a common finding.
used. arc. Alt A can be present in cases secondary to bone marrow inflictation by imploprolifeative disorder or Parvorius B19 infection. Peripheral smear examination Increased polychomatopith for age and the present in case age polychomatopith for age and the present in cold agalutini syndhome (CAS)/red cell fragments/ treatdops cells (taggestrive of bone marrow inflictation). Serum bilinubin and liver function tests (LFI) Normal/Increased Normal/Increased Normal/Increased Serum lactate dehydrogenase enzyme (LDH) The abe increased in hepatic disease too. Serum hemopexin and haptoglobin Decreased. "Unite routine examination Evidence of unitary RICs and haemoglobin. (Ferricyanide test) Evidence of unitary RICs and haemoglobin. (Ferricyanide test) Detection of underlying disorders Serum Increased. If E is suspected. Serum Increased and bloog area nitrogen (BUN) Detection of underlying disorders Serum Increased. Detection of underlying disorders. Serum Introduction (ferricyanide test) Detection of underlying disorders. Serum Introduction and biopsy If E is suspected. Serum Introduction and biopsy Detection of underlying disorders. Serum Introduction and biopsy If escilar in terage ferulas. Indicated if CAD Extrems </td <td></td> <td>Absolute reticulocyte count (ARC), and bone marrow responsiveness index (BMRI) are</td>		Absolute reticulocyte count (ARC), and bone marrow responsiveness index (BMRI) are
Reticulocytopenia in AIHA can be present in cases secondary to bone marrow infiltration by lymphopoliferative disorder or Parvovirus III2 infection. Peripheral smar examination Increased polychromatophils for age Normal/Increased Total control of the polychromatophils for age Serum bilinubin and liver function tests (LFI) Normal/Increased. Normal/Increased. Normal/Increased. Normal/Increased. Normal/Increased. Normal/Increased. Tit Specifically infinions to rule out AIHA with gipar cell hepatins (GCH). Serum hemopexin and haptoglobin Decreased. "IDII can be increased in hepatic disease too. Serum hemopexin and haptoglobin Unine routine examination Evidence of uninary REC and hamoglobin. Unine routine examination If ES is suspected. Unine routine examination If ES is suspected. Certain and blood urea nitrogen (BUN) If ES is suspected. Serum finamonofization" Detection of underlying disorders. Serum manunofization" Detection of underlying disorders. Serum finamonofization" Detection of underlying disorders. Serum finamonofization" Detection of underlying disorders. Serum finamonofization" Septifical dicon feares Anti-dSUNA, ANA, ant		used.
Peripheral smear examination Increased polychromotophils for age Peripheral smear examination Increased polychromotophils for age Normocytic/Macrocytic picture with micro spherocytes in w AHLA+/RBC age/pitrimities and rolloaux in cold age/pitrimities syndhome (CAS)/red cell fragments/ tearloop cells (uggestive of bone marrow infiltration). Serum bilinubin and liver function tests (LFI) Normal/Increased. *Normal/Increased. IPT Specifically in infinitions to rule out AHHA with giant cell hepathis (GCH). Serum hemopexin and haptoglobin IDE and be increased in hepatic disease too. Serum hemopexin and haptoglobin Decreased. "Unite routine examination Evidence of unitary RBCs and haemoglobin. Urine for hemosiderin Evidence of unitary hemosiderin after a week. (Perifyend) T-cell solution Evidence of unitary RBCs and haemoglobin. Urine for hemosiderin and blood urea nitrogen (BUN) If ES is suspected. Serum instruction of underlying disorders Perection of underlying disorders. Serum INIV, HBW, HCV Detection of underlying disorders. Anti-dSNA, ANA, and extractable nuclear antigens, anti- Detection of underlying disorders. 2glycoptonin antibodies, and lupus-Hite anticoggularis. Infections. Infectious screening A secological tests for Epstein-Barr virus and/or Mycoplasma		Reticulocytopenia in AIHA can be present in cases secondary to bone marrow
Peripheral sancar examination Increased polychromatophils for age Normocycle/Macrocycle picture with micro spherocycles in w AIIA2/RBC agglutinates and rodeaux in cold agglutinin synathrome (CAS)/red cell fragments/ teardrop cells (aggeutive of bose macrow infiltration). Presence of muchated RBCs UTF: Specifically in infants to rule out AIIAA with giant cell bepatits (GCII). Increased "LTF: Specifically in infants to rule out AIIAA with giant cell bepatits (GCII). Increased. "LTF: Specifically in infants to rule out AIIAA with giant cell bepatits (GCII). Increased. "LTF: Specifically in infants to rule out AIIAA with giant cell bepatits (GCII). Increased. "LTF: Specifically in infants to rule out AIIAA with giant cell bepatits (GCII). Increased. "LTF: Specifically in infants to rule out AIIAA with giant cell bepatits (GCII). Increased. "LTF: Specifically in infants to rule out AIIAA with giant cell bepatits (GCII). Increased. "LTF: Specifically in infants to rule out AIIAA with giant cell bepatits (GCII). Increased. "LTF: Specifically in infants to rule out AIIAA with giant cell bepatits (GCII). Increased. "LTF: Specifically in infants to rule out AIIAA with giant cell bepatits (GCII). Increased. "LTF: Specifically in the bepatit disease too. "LTF: Specifically in terage from and the specifical and the top and the specifical and the top and the specifical and the top and the specifical an		infiltration by lymphoproliferative disorder or Parvovirus B19 infection.
Normocytic/Macrocyte neuror with mero spherotyces in vAILAZ/RUC agglutiniats and onloakus in cold agglutinis syndrome (CAS)/ed cell fragments/ teadrop cells (suggestive of bone marrow infiltration). Serum bilirubin and liver function tests (LFT) Normal/Increased. "Normal in cases of milder haemolysis. LTT: Specifically in infants to rule out AIHA with giant cell hepatitis (GCH). Increased. Serum hemopexin and haptoglobin "LDT can be increased in hepatic disease too. Serum hemopexin and haptoglobin Exidence of urinary RBCs and haemoglobin. Increased urobilinogen Urine routine examination Exidence of urinary hemosiderin after a week. (Ferricipatide tests) Perpheral T cell subsets If ES is suspected. Serum Introper honesis with immunofisation* Detection of underlying disorders Zayteoprotein antibodies, and haproglobulins and deterophonesis with immunofisation Detection of underlying disorders Serum ITCL, HIBV, HCV Detection of underlying disorders. Ani-dSDA, ANA, ani-extractable nuclear antigens, ani-p Detection of underlying disorders. "Stream entrow aspinition and biopsy Infacted for CAD features in history, cauminution, haemogrant or smear suggesting possible marrow infiltration (presence of trantrop cells) Bone marrow aspinition and biopsy Infacted for Experime. Marry virus and/or Mycoplasma pneumonia if IgM Abs are direction. Provvirus, haematinic If ret	Peripheral smear examination	Increased polychromatophils for age
aggunantes and roueaux in coole aggunantes ynores (LAS)/red cei raggnenis/ teachorp cells suggestive of bone marrow infiltration). Presence of nucleated RBCs Scrum hierbain and liver function tests (LJT) Serum lactate dehydrogenase enzyme (LDH) Filt can be increased. *Normal: in cases of milder haemolysis LFT: Specifiedly in infants to rule out AII IA with giant cell hepatitis (GCI). Increased. *LDH can be increased in hepatic disease too. Serum hemopesin and haptoglobin Filt can be increased in hepatic disease too. Unine routine examination Urine for hemosiderin (Perricyanide test) Filt subsets Filt Si suspected. Serum immunoglobulins and electrophoresis with immunofistation* Serum function dhomes and loging filt Si suspected. Serum intrustority Serum function and biopsy Serum function and biopsy Serum function and biopsy filt FS is suspected. Serum function and biopsy Serum function, hemogen or sonear suggesting possible marrow infiltration (presence of transford case) Serum function, hemogen or neurosen suggesting possible marrow infiltration (presence of transford case) Filterication and biopsy in history, camination, hemogen or neuros compensation, ±dyscrythropoiesis, fabrosis, and clonal hymphogrofileration "Concurrent thrombocks, and hapus-like anticoagulant in theory, and age Frecticolog relation and biopsy in history, camination, hemogen or neuros compensation, ±dyscrythropoiesis, fabrosis, and clonal hymphogrofileration are detected. Dependent on symptoms, travel bitory, and age Freciologitopenia Osnooic gradient ektacytometry Autommune hymphogrofileration preshing since and case of transford services. Follow-up testing as needed with next-generation sequencing on ALPS or PID gene parels Next-generation sequencing (NGS) paral for RIC membrane disordes, RIC campropathies, and congenitat dyscrythropoietic anaemia. Fow cytometry Subpopulations.		Normocytic/Macrocytic picture with micro spherocytes in w AIHA±/RBC
relating Coss Gaggestor of moleculation (BRCs Serum bilirubin and liver function tests (LFT) Normal/Increased. "Normal/Increased." "Normal/Increased." Serum halten dehydrogenase enzyme (LDH) Increased. "LT": Specifically in infants to rule out AHIA with giant cell hepatitis (GCH). Increased. "LDH can be increased in hepatic disease too. Urine routine examination Evidence of urinary RBCs and haemoglobin. Increased. TES is suspected. Serum Hick tests If ES is suspected. Serum Intro, IBV, IBV, IICV Detection of underlying disorders Serum Intro, IBV, IBV, IICV Detection of underlying disorders. Anti dSDA, ANA, and extractable nuclear antigens, antig Detection of underlying disorders. Serum IIV, IBV, IICV Detection of underlying disorders. Anti dSDA, ANA, and extractable nuclear antigens, and ig Detection of underlying disorders. Indicated if CAD features Indicated if CAD features Infectious screening A serological test for Epstein–Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Pervovirus, haematinic If recluotypenia Infectious screening A serological test for Epstein–Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Pe		agglutinates and rouleaux in cold agglutinin syndrome (CAS)/red cell tragments/
Serum bilirubin and liver function tests (LFT) Inverse of middle haemodysis. Serum latitude dehydrogenase enzyme (LDH) Increased. *Normal/Increased. *Normal/Increased. *UDH can be increased in hepatic disease too. Serum hemopesin and haptoglobin *Unite courtine examination Decreased. *Uhne examination *Vidence of unitary RBCs and haemoglobin. Unite outine examination Increased in hepatic disease too. Urine routine examination Evidence of unitary RBCs and haemoglobin. Unite for hemosiderin First is suspected. Serum reatinine and blood urea nitrogen (BUN) If ES is suspected. Serum routine examination* Detection of underlying disorders. Serum routine and blood urea nitrogen (BUN) Detection of underlying disorders. Serum routine and blood urea nitrogen (BUN) If ES is suspected. Serum routine and blood urea nitrogen (BUN) Detection of underlying disorders. Serum row aspiration and biopsy Detection of underlying disorders. * Specifically in teenage females. Indicated if CAD features in history, examination, haemogram or smear suggesting possible marrow infiltration (presence of cardrop cells) Evidence of home marrow compensation, ±dyserythropoiesis, fibrosis, and clonal lymphoproliferation Concurrent (t		Presence of nucleated RBCs
control number and the function of the properties of milder haemolysis. *Normal: in cases of milder haemolysis. LFT: Specifically in infants to rule out AIHA with giant cell hepatitis (GCH). Increased. Serum harting and haptoglobin *LDH can be increased in hepatic disease too. Urine routine examination Evidence of urinary RBGs and haemoglobin. Urine for hemosiderin Evidence of urinary RBGs and haemoglobin. (Ferricganide text) Ferries of urinary RBGs and haemoglobin. Peripheral T-cell subsets If ES is suspected. Serum HW, HW, HCV Detection of underlying disorders Serum HW, HW, HCV Detection of underlying disorders. Anti-dsDNA, ANA, anti-extractable nuclear antigens, anti-β Detection of underlying disorders. 2glycoprotein antibodies, and lupus-like anticoagulants. Bote extraop cells) Bone marrow aspiration and biopsy Evidence of bone marrow compensation, ±dyscrythropoiesis, fibrosis, and clonal lymphopoliferation. Infectious screening A serological test for Epstein–Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Autainmule lymphopoliferation Freiciloopypenia Autainmule lymphopoliferation Freiciloopypenia Autainmule lymphopoliferation Freiciloopypenia Rerevolytopenia Freiciloopypenia<	Serum bilirubin and liver function tests (LFT)	Normal/Increased
LPT: Specifically in infants to rule our AIHA with giant cell hepaticils (GCI).Serum hactate dehydrogenase enzyme (LDH)Increased. *LDH can be increased in hepatic disease too.Serum hemopesin and haptoglobinDecreased. *Haptoglobin can be increased in hepatic disease too.Urine routine examinationEvidence of urinary RBCs and haemoglobin. Increased urobilinogenUrine for hemosiderinEvidence of urinary RBCs and haemoglobin. Intereased urobilinogenUrine for hemosiderinEvidence of urinary RBCs and haemoglobin. Intereased in of underlying disordersSerum IIIV, IIBV, HCVDetection of underlying disorders.Serum IIIV, IIBV, HCVDetection of underlying disorders.Anti-SbDXA, NA, anti-streatable nuclear antigens, anti- 2glycoprotein antibodies, and lopus-like anticoagulants. Prescrictally in teenage females.Bone marrow aspiration and biopsyInfective antimotor, haemogram or smear suggesting possible marrow infiltration (presence of caratrop cells) Evidence of thomobecrypoenia and/or neutropenia, unusual or prolonged reiculocytopenia, hymphadenopathy, or organomegaly without evidence of concurrent EVI infection.EVI infectiousConcurrent Hhomobecrypoenia and/or neutropenia, unusual or prolonged reiculocytopenia, hymphadenopathy, or organomegaly without evidence of concurrent tells intory, and age Prevovins, haematinicInfectious sereeningI	berum binrubin and nyer runedon tests (Fr T)	*Normal: in cases of milder haemolysis.
Serum lactate dehydrogenase enzyme (LDH) Increased. *LDH can be increased in hepatic disease too. Serum hemopexin and haptoglobin "LDH can be increased in hepatic disease too. Urine routine examination Evidence of urinary BRCs and haemoglobin. Urine for hemosiderin Evidence of urinary themosiderin after a week. (Ferricyandic test) Evidence of urinary themosiderin after a week. Peripheral T-cell subsets If ES is suspected. Serum inmunoglobulins and electrophoresis with Detection of underlying disorders Serum Hy, HBV, HCV Detection of underlying disorders. Indicated if CAD features Indicated if CAD features Bone marrow aspiration and biopsy A scological test for Epstein-Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Pervoirus, haematinic If retiouostoporpia Infectious screening panel <td< td=""><td></td><td>LFT: Specifically in infants to rule out AIHA with giant cell hepatitis (GCH).</td></td<>		LFT: Specifically in infants to rule out AIHA with giant cell hepatitis (GCH).
*LDH can be increased in hepatic disease too.Serum hemopexin and haptoglobinDecreased.*Haptoglobin can be increased in hepatic disease too.Urine routine examinationEvidence of urinary RBCs and haemoglobin.Urine for hemosiderinEvidence of urinary hBCs and haemoglobin.(Ferricyande test)Perfyheral T-cellDerighteral T-cellSubsetsSerum creatinine and blood area nitrogen (BUN)If ES is suspected.Serum creatinine and blood area nitrogen (BUN)Detection of underlying disordersSerum flv, HBV, HCVDetection of underlying disorders.Sarui daDNA, ANA, anti-extractable nuclear antigens, anti-Detection of underlying disorders.2glycorportic natibodies, and lapus-like anticoagulants.Specifically in tecnage females.Bone marrow aspiration and biopsyIndicate if CAD featuresInfectious sereeningA serological test for Epstein-Barr virus and/or Mycoplasma preumonia if lgM Abs are detected.Derevirus, haematinicIf reticulocytopeniaOsmotic gradient ekaryometryIncreased on symptoms, travel history, and ageParvovirus, haematinicIf reticulocytopeniaOsmotic gradient ekaryometryIncreased on symptoms, travel history, and ageNext-generation sequencing (NGS) panel for RBC servering panelTo rule out other causes of haemoglobinuria (PNH) & lymphocyte subpopulations.EMA-binding, high-performance liquid chromatography, erywhorybeit enzyme activities, (GoPD, PKD and other rar valves, hermidiction)To rule out other causes of haemolysis congenial microangiopathies (prosthetic heart wates, hermidiction)Parvov	Serum lactate dehydrogenase enzyme (LDH)	Increased.
Serum hemopexin and haptoglobin Decreased. "Haptoglobin can be increased in hepatic disease too. Urine routine examination Evidence of urinary RBCs and haemoglobin. Increased urobilinogen Increased urobilinogen (Ferricyanide test) Evidence of urinary hemosiderin after a week. (Ferricyanide test) If ES is suspected. Serum rentinine and blood urea nitrogen (BUN) If ES is suspected. Serum rentinine and blood urea nitrogen (BUN) Detection of underlying disorders Serum HU, HBV, HCV Detection of underlying disorders. Anti-dsDNA, ANA, anti-extractable nuclear antigens, anti-β Detection of underlying disorders. 2glycoprotein antibodies, and lapus-lake anticogularis. * Specifically in teenage (emales. Bone marrow aspiration and biopsy Indicated if CAD Fatures "in history, examination, haemogram or smear suggesting possible marrow infiltration (presence of teardorp cells) Evidence of bone marrow compensation, ±dyserythropoiesis, fibrosis, and clonal lymphoproliferation Parvovirus, haematinic If reciculocytopenia Osmoir gradient ektacytometry Increased Orni and decreased Elmax. Autoinmune lymphoproliferative syndromes (ALPS) Follow-up testing a needed with next-generation sequencing on ALPS or PID gene parels Next-generation sequencing (NGS) parel for RBC Increased orni and decreased Elmax. Next-generatione sequencing p		*LDH can be increased in hepatic disease too.
"Haptoglobin can be increased in hepagic disease too.Urine routine examinationEvidence of urinary RBCs and haemoglobin. Increased urobilinogenUrine for hemosiderinEvidence of urinary hemosiderin after a week.(Ferricyanide test)If ES is suspected.Serum immunoglobulins and electrophoresis with immunofixation*Detection of underlying disordersSerum immunoglobulins and electrophoresis with immunofixation*Detection of underlying disordersAnti-dSDNA, NNA, anti-extractable nuclear antigens, anti- 2glycoprotein antibodies, and lupus-like anticoagulants.Detection of underlying disorders.Bone marrow aspiration and biopsyEvidence of tearange females.Indicated if CAD features in history, examination, haemogram or smear suggesting possible marrow infiltration (gresence of teardrop cells)Evidence of support of the disordersSconurrent thrombocytopenia and/or neutropenia, unusual or prolonged reticulocytopenia, hymphadenopathy, or organomegaly without evidence of concurrent EBV infection.Infectious screeningIf reticulocytopenia are detected. Dependent on symptoms, travel history, and ageParvovirus, haematinicIf nereased Omin and decreased EImax.Autoimmune lymphoproliferative syndromes (ALPS) serecening pandFollow-up testing as needed with next-generation sequencing on ALPS or PID gene panelsEffor cytoperityTorule out secondary disorders.EMA-binding, high-performance liquid chromatography erythorpoietic anaemi.Torule out secondary disorders.Flow cytometryTorule out secondary disorders.EMA-binding, high-performance liquid chromatographyTorule o	Serum hemopexin and haptoglobin	Decreased.
Urine routine examinationEvidence of urinary RBCs and haemoglobin. Increased urobilinogenUrine for hemosiderinEvidence of urinary RBCs and haemoglobin.(Ferriqyanide test)Evidence of urinary hemosiderin after a week.Peripheral T-cell subsetsIf ES is suspected.Serum metatinine and blood urea nitrogen (BUN)If ES is suspected.Serum inmunofysiton*Detection of underlying disordersSerum HIV, HBV, HCVDetection of underlying disorders.Anti-dSDNA, NNA, anti-extractable nuclear antigens, anti-\$Petection of underlying disorders.2glycoprotein antbodies, and hupus-like anticoagulants.* Specifically in tenage females.Bone marrow aspiration and biopsyIndicated if CAD features in history, examination, haemogram or smear suggesting possible marrow infiltration (presence of leadrop cells)Evidence of bone marrow compensation, ±dyserythropoiesis, fibrosis, and clonal lymphoproliferation *Concurrent thrombocytopenia and/or neutropenia, unusual or prolonged reticulocytopeniaInfectious screeningA serological test for Epstein-Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected.Pervovirus, haematinicIf reticulocytopeniaNext-generation sequencing (NGS) panel for RBC membane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia.Follow-up testing as needed with next-generation sequencing on ALPS or PID gene panelsEMA-binding, high-performance liquid chromatography, erythropoietic anaemia.To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations.EMA-binding, high-performance liquid chromatography, erythropyte enzyme defects, hemo		*Haptoglobin can be increased in hepatic disease too.
Increased urobilinogen Increased urobilinogen Urine for hemosiderin Evidence of urinary hemosiderin after a week. (Ferricyanide test) If ES is suspected. Serum reatinine and blood urea nitrogen (BUN) If ES is suspected. Serum immunoglobulins and electrophoresis with immunofixation* Detection of underlying disorders Serum HIV, HBV, HCV Detection of underlying disorders. Anti-dSDNA, ANA, anti-extractable nuclear antigens, anti-3 Detection of underlying disorders. 2glycoprotein antibodies, and lupus-like anticoagulants. Peterction of underlying disorders. Bone marrow aspiration and biopsy Indicated if CAD features in history, examination, haemogram or smear suggesting possible marrow infiltration (presence of teardrop cells) Evidence of bone marrow compensation, ±dyscrythropoiesis, fibrosis, and clonal lymphoproliferation Versence of concurrent EBV infection. Infectious screening A serological test for Epstein–Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Dependent on symptoms, travel history, and age Follow-up testing as needed with next-generation sequencing on ALPS or PID gene genels Next-generation sequencing (NGS) panel for RBC membrane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia. To rule out secondary disorders. Folwe uptometry To rule out secondary disorders. To rule out seconda	Urine routine examination	Evidence of urinary RBCs and haemoglobin.
Urine for hemosiderin Evidence of urinary hemosiderin after a week. (Ferriqyanic tests) Fersion of underlying disorders Peripheral T-cell subsets If ES is suspected. Serum reatinine and blood urea nitrogen (BUN) If ES is suspected. Serum immunoglobulins and electrophoresis with immunofisation* Detection of underlying disorders Serum IMIV, HBV, HCV Detection of underlying disorders. Anti-dsDNA, ANA, anti-extractable nuclear antigens, anti-\$ * Specifically in trenage females. Bone marrow aspiration and biopsy Indicated if CAD features in history, examination, hemogram or smear suggesting possible marrow infiltration (presence of teardrop cells) Evidence of bone marrow compension, ±dyscrythropoisis, fibrosis, and clonal lymphoproliferation Infectious screening A scrological test for Epstein–Barr virus and/or Nevoplasma pneumonia if IgM Abs are detected. Dependent on symptoms, travel history, caread Omin and decreased Elmax. Follow-up testing as needed with next-generation sequencing on ALPS or PID gene panels. Next-generation sequencing (NGS) panel for RBC To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations. Folw cytometry To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations. EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare varexe. To rule out other causes of		Increased urobilinogen
 (Perryande test) Peripheral T-cell subsets If ES is suspected. Serum and blood urea nitrogen (BUN) If ES is suspected. Serum HTR, HBV, HCV Detection of underlying disorders Anti-dsDNA, ANA, anti-extractable nuclear antigens, anti-β 2glycoprotein antibodies, and lupus-like anticoagulants. Bone marrow aspiration and biopsy Detection of underlying disorders. * Specifically in teenage females. Indicated if CAD Features in history, examination, haemogram or smear suggesting possible marrow infiltration (presence of teardrop cells) Evidence of bone marrow compensation, ±dyserythropoiesis, fibrosis, and clonal lymphoproliferation * Concurrent thrombocytopenia and/or neutropenia, unusual or prolonged reticulocytopenia, lymphadenopathy, or organomegaly without evidence of concurrent EBV infection. A serological test for Epstein-Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Dependent on symptoms, travel history, and age Parvovirus, haematinic If reticulocytopenia Parvovirus, haematinic Proveytometry Increased Omin and decreased Elmax. Follow-up testing as needed with next-generation sequencing on ALPS or PID gene panels Next-generation sequencing (NGS) panel for RBC membrane disorders, RBC enzymopathies, and congenital dyserythropotie is anaemia. Flow eytometry To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations. EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (GoPD, PKD and other rare valves, theomatic endocarditis) 	Urine for hemosiderin	Evidence of urinary hemosiderin after a week.
Perpferal 1-cell subsets If ES is suspected. Serum creatinine and blood urea nitrogen (BUN) If ES is suspected. Serum HIL, HBV, HCV Detection of underlying disorders Anti-dsDNA, ANA, anti-extractable nuclear antigens, anti-β Detection of underlying disorders. 2glycoprotein antibodies, and hupus-like anticoagulants. Detection of underlying disorders. Bone marrow aspiration and biopsy FESE suspected. Indicated if CAD features in history, examination, haemogram or smear suggesting possible marrow infiltration (presence of toen arrow compensation, ±dyserythropoiesis, fibrosis, and elonal lymphopoliferation * Concurrent Hormbocytopenia and/or neutropenia, unusual or prolonged reticulocytopenia, lymphadenopathy, or organomegaly without evidence of concurrent EBV infection. Infectious screening A serological test for Epstein-Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Dependent on symptoms, travel history, and age If reticulocytopenia Parvovirus, haematinic If reticulocytopenia Osmotic gradient ektacytometry Increased Omin and decreased Elmax. Follow-up testing as needed with next-generation sequencing on ALPS or PID gene parcels Follow-up testing as needed with next-generation sequencing on ALPS or PID gene parcels Next-generation sequencing (NGS) panel for RBC To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations. <td>(Ferricyanide test)</td> <td></td>	(Ferricyanide test)	
Serum meanuoglobulins and electrophoresis with immunofixation* If ES is suspected. Serum immunoglobulins and electrophoresis with immunofixation* Detection of underlying disorders Anti-dsDNA, ANA, anti-extractable nuclear antigens, anti-β Detection of underlying disorders. Anti-dsDNA, ANA, anti-extractable nuclear antigens, anti-β Detection of underlying disorders. Some marrow aspiration and biopsy To camination, haemogram or smear suggesting possible marrow infiltration (presence of teardrop cells) Evidence of bone marrow compensation, ±dyserythropoiesis, fibrosis, and clonal lymphoproliferation To rele out personal and/or neutropenia, unusual or prolonged reticulocytopenia, lymphadenopathy, or organomegaly without evidence of concurrent EBV infection. Infectious screening A serological test for Epstein–Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Osmotic gradient ektacytometry Increased Omin and decreased EImax. Autoimmune lymphoproliferative syndromes (ALPS) screening panel To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations. Flow cytometry To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations.	Peripheral I-cell subsets	If ES is suspected.
Serum immunogioulins and electrophoresis with Detection of underlying disorders Serum HIV, HBV, HCV Detection of underlying disorders Anti-dsDNA, ANA, anti-extractable nuclear antigens, anti-3 Detection of underlying disorders. 2glycoprotein antibodies, and lupus-like anticoagulants. * Specifically in teenage females. Bone marrow aspiration and biopsy Indicated if CAD features in history, examination, haemogram or smear suggesting possible marrow infiltration (presence of teardrop cells) Evidence of bone marrow compensation, ±dyserythropoiesis, fibrosis, and clonal lymphoproliferation "Concurrent thrombocytopenia and/or neutropenia, unusual or prolonged reticulocytopenia, lymphadenopathy, or organomegaly without evidence of concurrent EBV infection. Infectious screening A serological test for Epstein-Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Dependent on symptoms, travel history, and age Increased Omin and decreased EImax. Autoimmune lymphoproliferative syndromes (ALPS) screening panel Follow-up testing as needed with next-generation sequencing on ALPS or PID gene panels Next-generation sequencing (NGS) panel for RBC membrane disorders. To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations. EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones) To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies,	Serum creatinine and blood urea nitrogen (BUN)	It ES is suspected.
Serum HIV, HBY, HCV Detection of underlying disorders Anti-dsDNA, ANA, anti-extractable nuclear antigens, anti-β Detection of underlying disorders. Zeytcoprotein antibodies, and lupus-like anticoagulants. Detection of underlying disorders. Bone marrow aspiration and biopsy Specifically in teenage females. Indicated if CAD features in history, examination, haemogram or smear suggesting possible marrow infiltration (presence of bone marrow compensation, ±dyserythropoiesis, fibrosis, and clonal lymphoproliferation Infectious screening Concurrent thromboeytopenia and/or neutropenia, unusual or prolonged reticulocytopenia, lymphadenopathy, or organomegaly without evidence of concurrent EBV infection. A serological test for Epstein–Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Dependent on symptoms, travel history, and age Parvovirus, haematinic If reticulocytopenia Increased Omin and decreased Elmax. Osmotic gradient ektacytometry Increased Omin and decreased Elmax. Autoimmune lymphoproliferative syndromes (ALPS) screening panel Follow-up testing as needed with next-generation sequencing on ALPS or PID gene panels Next-generation sequencing (NGS) panel for RBC To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations. FeMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (GoPD, PKD and other rar ones) To rule out other causes of haemolysis: congenital memb	immunofixation*	Detection of underlying disorders
Anti-dsDNA, ANA, Anti-extractable nuclear antigens, anti-β Detection of underlying disorders. 2glycoprotein antibodies, and lupus-like anticoagulants. * Specifically in teenage females. Bone marrow aspiration and biopsy Indicated if CAD features in history, examination, haemogram or smear suggesting possible marrow infiltration (presence of teardrop cells) Evidence of bone marrow compensation, ±dyserythropoiesis, fibrosis, and clonal lymphoproliferation Infectious screening A serological test for Epstein–Barr virus and/or neutropenia, unusual or prolonged reticulocytopenia (hymphoproliferation symptoms, travel history, and age Parvovirus, haematinic If reticulocytopenia Osmotic gradient ektacytometry Increased Omin and decreased EImax. Autoimmune lymphoproliferative syndromes (ALPS) Follow-up testing as needed with next-generation sequencing on ALPS or PID gene panels Next-generation sequencing (NGS) panel for RBC To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations. Flow cytometry To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations. EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rar ones) To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, theumatic endocarditis)	Serum HIV, HBV, HCV	Detection of underlying disorders
2gycoproten antbodies, and tupus-like anticoagulants.* Specifically in teenage temales.Bone marrow aspiration and biopsyIndicated if CAD features in history, examination, haemogram or smear suggesting possible marrow infiltration (presence of teardrop cells) Evidence of bone marrow compensation, ±dyserythropoiesis, fibrosis, and clonal lymphoproliferation *Concurrent thrombocytopenia and/or neutropenia, unusual or prolonged reticulocytopenia, lymphadenopathy, or organomegaly without evidence of concurrent EBV infection.Infectious screeningA serological test for Epstein–Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Dependent on symptoms, travel history, and ageParvovirus, haematinicIf reticulocytopenia Increased Omin and decreased EImax. Follow-up testing as needed with next-generation sequencing on ALPS or PID gene panelsNext-generation sequencing (NGS) panel for RBC membrane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia.To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations.EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rar ons)To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, theumatic endocarditis)	Anti-dsDNA, ANA, anti-extractable nuclear antigens, anti- β	Detection of underlying disorders.
Bone marrow aspiration and biopsyIndicated if CAD returesBone marrow aspiration and biopsyIndicated if CAD returesIn history, examination, haemogram or smear suggesting possible marrow infiltration (presence of teardrop cells) Evidence of bone marrow compensation, ±dyserythropoiesis, fibrosis, and clonal lymphoproliferation *Concurrent thrombocytopenia and/or neutropenia, unusual or prolonged reticulocytopenia, lymphadenopathy, or organomegaly without evidence of concurrent EBV infection.Infectious screeningA serological test for Epstein–Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Dependent on symptoms, travel history, and ageParvovirus, haematinicIf reticulocytopenia If reticulocytopeniaOsmotic gradient ektacytometryIncreased Omin and decreased EImax. Follow-up testing as needed with next-generation sequencing on ALPS or PID gene panelsNext-generation sequencing (NGS) panel for RBC membrane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia.To rule out secondary disorders.Fow cytometryTo rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations.EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones)To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, thematic endocarditis)	2glycoprotein antibodies, and lupus-like anticoagulants.	* Specifically in teenage temales.
Initiation, nation of shear suggesting possible matrix winitiation(presence of teardrop cells)Evidence of bone marrow compensation, ±dyserythropoiesis, fibrosis, and clonallymphoproliferation*Concurrent thrombocytopenia, lymphadenopathy, or organomegaly without evidence of concurrentEBV infection.A serological test for Epstein–Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected.Dependent on symptoms, travel history, and ageParvovirus, haematinicOsmotic gradient ektacytometryAutoimmune lymphoproliferative syndromes (ALPS) screening panelNext-generation sequencing (NGS) panel for RBC membrane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia.Flow cytometryEMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones)Carbon ConstructionCarbon ConstructionCarbon ConstructionCarbon ConstructionCarbon ConstructionCarbon ConstructionCarbon ConstructionCarbon ConstructionCarbon ConstructionCarbon ConstructionConstructionCarbon ConstructionCarbon Construction	Bone marrow aspiration and biopsy	Indicated if CAD features
Evidence of bone marrow compensation, ±dyserythropoiesis, fibrosis, and clonal lymphoproliferation *Concurrent thrombocytopenia and/or neutropenia, unusual or prolonged reticulocytopenia, lymphadenopathy, or organomegaly without evidence of concurrent EBV infection. A serological test for Epstein–Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Dependent on symptoms, travel history, and age Parvovirus, haematinic Osmotic gradient ektacytometry Autoimmune lymphoproliferative syndromes (ALPS) screening panel Next-generation sequencing (NGS) panel for RBC membrane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia. Flow cytometry EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rae ones)		(presence of teardrop cells)
Iymphoproliferation*Concurrent thrombocytopenia and/or neutropenia, unusual or prolonged reticulocytopenia, lymphadenopathy, or organomegaly without evidence of concurrent EBV infection.Infectious screeningA serological test for Epstein–Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Dependent on symptoms, travel history, and ageParvovirus, haematinicIf reticulocytopenia If reticulocytopeniaOsmotic gradient ektacytometryIncreased Omin and decreased EImax.Autoimmune lymphoproliferative syndromes (ALPS) screening panelFollow-up testing as needed with next-generation sequencing on ALPS or PID gene panelsNext-generation sequencing (NGS) panel for RBC membrane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia.To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations.EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones)To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, theumatic endocarditis)		Evidence of bone marrow compensation, ±dvservthropoiesis, fibrosis, and clonal
*Concurrent thrombocytopenia and/or neutropenia, unusual or prolonged reticulocytopenia, lymphadenopathy, or organomegaly without evidence of concurrent EBV infection.Infectious screeningA serological test for Epstein–Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Dependent on symptoms, travel history, and ageParvovirus, haematinicIf reticulocytopeniaOsmotic gradient ektacytometryIncreased Omin and decreased EImax.Autoimmune lymphoproliferative syndromes (ALPS) screening panelFollow-up testing as needed with next-generation sequencing on ALPS or PID gene panelsNext-generation sequencing (NGS) panel for RBC membrane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia.To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations.EMA-binding, high-performance liquid chromatography, ensyTo rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, heumatic endocarditis)		lymphoproliferation
reticulocytopenia, lymphadenopathy, or organomegaly without evidence of concurrent EBV infection. A serological test for Epstein–Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Dependent on symptoms, travel history, and age Parvovirus, haematinic If reticulocytopenia Osmotic gradient ektacytometry Increased Omin and decreased EImax. Autoimmune lymphoproliferative syndromes (ALPS) screening panel Follow-up testing as needed with next-generation sequencing on ALPS or PID gene panels To rule out secondary disorders. To rule out secondary disorders. Folw cytometry To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations. EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones) To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, theumatic endocarditis)		*Concurrent thrombocytopenia and/or neutropenia, unusual or prolonged
EBV infection.Infectious screeningA serological test for Epstein–Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Dependent on symptoms, travel history, and ageParvovirus, haematinicDependent on symptoms, travel history, and ageOsmotic gradient ektacytometryIncreased Omin and decreased EImax.Autoimmune lymphoproliferative syndromes (ALPS) screening panelFollow-up testing as needed with next-generation sequencing on ALPS or PID gene panelsNext-generation sequencing (NGS) panel for RBC membrane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia.To rule out secondary disorders.Flow cytometryTo rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations.EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones)To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, theumatic endocarditis)		reticulocytopenia, lymphadenopathy, or organomegaly without evidence of concurrent
Infectious screeningA serological test for Epstein–Barr virus and/or Mycoplasma pneumonia if IgM Abs are detected. Dependent on symptoms, travel history, and ageParvovirus, haematinicIf reticulocytopeniaOsmotic gradient ektacytometryIncreased Omin and decreased EImax.Autoimmune lymphoproliferative syndromes (ALPS) screening panelFollow-up testing as needed with next-generation sequencing on ALPS or PID gene panelsNext-generation sequencing (NGS) panel for RBC membrane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia.To rule out secondary disorders.Flow cytometryTo rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations.EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones)To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, rheumatic endocarditis)		EBV infection.
are detected.Dependent on symptoms, travel history, and ageParvovirus, haematinicIf reticulocytopeniaOsmotic gradient ektacytometryIncreased Omin and decreased EImax.Autoimmune lymphoproliferative syndromes (ALPS) screening panelFollow-up testing as needed with next-generation sequencing on ALPS or PID gene panelsNext-generation sequencing (NGS) panel for RBC membrane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia.To rule out secondary disorders.Flow cytometryTo rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations.EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones)To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, rheumatic endocarditis)	Infectious screening	A serological test for Epstein–Barr virus and/or Mycoplasma pneumonia if IgM Abs
Dependent on symptoms, travel history, and ageParvovirus, haematinicIf reticulocytopeniaOsmotic gradient ektacytometryIncreased Omin and decreased EImax.Autoimmune lymphoproliferative syndromes (ALPS) screening panelFollow-up testing as needed with next-generation sequencing on ALPS or PID gene panelsNext-generation sequencing (NGS) panel for RBC membrane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia.To rule out secondary disorders.Flow cytometryTo rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations.EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones)To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, rheumatic endocarditis)		are detected.
Parvovirus, haematinic If reticulocytopenia Osmotic gradient ektacytometry Instory, and age Osmotic gradient ektacytometry If reticulocytopenia Autoimmune lymphoproliferative syndromes (ALPS) Follow-up testing as needed with next-generation sequencing on ALPS or PID gene panels To rule out secondary disorders. To rule out secondary disorders. Flow cytometry To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations. EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones) To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, rheumatic endocarditis)		travel history and age
In recence (specific Osmotic gradient ektacytometryIn recence (specific and decreased Elmax.Autoimmune lymphoproliferative syndromes (ALPS) screening panelFollow-up testing as needed with next-generation sequencing on ALPS or PID gene panelsNext-generation sequencing (NGS) panel for RBC membrane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia.To rule out secondary disorders.Flow cytometryTo rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations.EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones)To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, rheumatic endocarditis)	Parvovirus haematinic	If reticulocytopenia
Autoimmune lymphoproliferative syndromes (ALPS) Follow-up testing as needed with next-generation sequencing on ALPS or PID gene screening panel panels Next-generation sequencing (NGS) panel for RBC To rule out secondary disorders. membrane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia. To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations. EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones) To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, rheumatic endocarditis)	Osmotic gradient ektacytometry	Increased Omin and decreased Elmax
Screening panelpanelsNext-generation sequencing (NGS) panel for RBC membrane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia.To rule out secondary disorders.Flow cytometryTo rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations.EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones)To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, rheumatic endocarditis)	Autoimmune lymphoproliferative syndromes (ALPS)	Follow-up testing as needed with next-generation sequencing on ALPS or PID gene
Next-generation sequencing (NGS) panel for RBC membrane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia.To rule out secondary disorders.Flow cytometryTo rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations.EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones)To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, rheumatic endocarditis)	screening panel	panels
membrane disorders, RBC enzymopathies, and congenital dyserythropoietic anaemia. Flow cytometry To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations. EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones) To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, rheumatic endocarditis)	Next-generation sequencing (NGS) panel for RBC	To rule out secondary disorders.
dyserythropoietic anaemia.To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations.Flow cytometryTo rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations.EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones)To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, rheumatic endocarditis)	membrane disorders, RBC enzymopathies, and congenital	
Flow cytometry To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte subpopulations. EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones) To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, rheumatic endocarditis)	dyserythropoietic anaemia.	
EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones) To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, rheumatic endocarditis)	Flow cytometry	To rule out paroxysmal nocturnal haemoglobinuria (PNH) & lymphocyte
EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones) To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, rheumatic endocarditis)		subpopulations.
EMA-binding, high-performance liquid chromatography, erythrocyte enzyme activities (G6PD, PKD and other rare ones) To rule out other causes of haemolysis: congenital membrane and enzyme defects, hemoglobinopathies, thrombotic and mechanical microangiopathies (prosthetic heart valves, rheumatic endocarditis)		
ones) ones (GOPD, PND and other rare ones) construction of the second se	EMA-binding, high-performance liquid chromatography,	To rule out other causes of haemolysis: congenital membrane and enzyme defects,
· ····································	ones)	valves, rheumatic endocarditis)

T 1	1	2	D ·	1	1 1	1 1	1 .	1	1 1	1+ 1	• 1	• . •	. •	• 1• . 1	•	
l at	ne.	1.	Basic 2	and	advanced	- la	boratory.	molecu	lar and	radio	logical	investion in the second	rations	indicated	1 n	AIHA
I UL		<u> </u>	Duble t	1114	uu vuiiceu	1.0	borator y	morecu	iui uiiu	induitor	ogical	III v Couly	Jaciono	mancatea		T T T T T T

Contd...

	Table 2: Contd
Laboratory and Radiological Investigations required	Remark ^[1,6,7]
Tests for allo and autoantibodies in serum, eluate, identification of antibody specificity, immunoabsorbance techniques, and extended RBC genotyping.	To rule out DHTRs, HDFN, and passenger lymphocyte syndrome.
Computed tomography of chest, abdomen, and pelvis	CAD (Cold agglutinin disease) at diagnosis and in relapsed/refractory WAIHA

π 1	1	2	A 1	1 1	1	+ 1	• •	. •	• 1	•	1 . 1		•.1	A 7	ТТ Т	
1.21	nle	.	Ad	difional	serolo	orical	Investi	oations.	regulired	1n se	lected	natients	with		гн	A
1 4		· • •	110	antional	scrolo	gicai	mvcou	gations	requireu	III SC.	iccicu	patiento	VV I LII	111		1 1

Investigations required	Possible outcome ^[1,7]
DAggT (Double agglutination test)	If DAT positive for C3d±IgG
Cold antibody titre	If DAggT positive
Red cell eluate	If monospecific: DAT-negative with a strong suspicion of AIHA.
Donath Landsteiner	If DAT is positive for C3d±IgG and i) DAggT-negative or insignificant CAs and ii) Age, 18 years or haemoglobinuria or cold-associated symptoms or atypical serology
The thermal range of cold Abs	If the clinical significance of cold auto agglutinin is unclear.
Enhanced DAT assays: a.) modified DAT with LISS at 4 °C. b.) DAT assays utilizing reagents such as anti-IgA and anti-IgM (Double DAT) c.) DAT by flowcytometry to detect RBC-bound Abs	In case of suspicion of DAT negative AIHA.
IAT	To look for the presence of coexisting allo Abs.

IAT



Figure 5: Flow chart for the sequence for serological diagnosis of DAT negative AIHA[11]

with AIHA may present as a clinical emergency with increased transfusion demand and poor prognosis as observed by Fattizo B et al. in 13 severe, refractory cases with fatal outcomes. In comparison with ARC, bone marrow responsiveness index (BMRI) is a better parameter, with a cut-off value <121; it discriminates haemolysis with synchronous reticulocytopenia with sensitivity and specificity of 90% and 65%, respectively, in congenital dyserythropoietic Anemias (CDA) patients^[14]

BMRI = Patient's absolute reticulocyte count \times (patient's Hb/ normal Hb for age and sex)^[12,14]

Conclusion: AIHA is a heterogeneous group of disorders wherein the aetiology remains elusive, but the molecular mechanisms underlying haemolysis and the associated complications are fairly well understood now. The categorization of AIHA as cold or warm or mixed type has a significant bearing on the treatment options available. The treatment should be individualized with an emphasis on the bone marrow picture, e.g., presence/absence of dyserythropoiesis, fibrosis, degree of bone marrow compensation, and clonal lymphoproliferation. It is needless to say that various pathologies associated with secondary AIHA cases like autoimmune diseases, malignancies, and immunodeficiencies have additional immune-mediated haemolytic processes as compared to the primary disease. With the evolution of molecular testing, the bracket of primary AIHA is getting shortened and the distinction between primary and secondary disorders seems to be more and more arbitrary.

Finally, there is the increasing emergence of complex and severe entities, particularly AIHA developing after haemopoietic stem cell transplantation and AIHA associated with novel anticancer drugs such as checkpoint inhibitors, which represent a clinical challenge for complications and fatal outcomes.

Lastly, there is the emergence of a new set of severe cases in the setting of AIHA secondary to HSCT and AIHA secondary to newer anticancer agents like checkpoint inhibitors, which pose a challenge for management. The increasing laboratory and molecular testing have enabled better risk stratification of the patients and diagnosis of underlying associated clinical syndromes.

Abbreviations

WAIHA	: Warm autoimmune haemolytic anaemia.
HA	: Haemolytic anaemia.
Abs	: Antibodies.
RBC	: Red blood cells.
DAT	: Direct antiglobulin test.
CLPD	: Chronic lymphoproliferative disorder.
CTT	: Conventional tube test.
LISS	: Low ionic strength solution
CAD	: Cold agglutinin disease.
CAS	: Cold agglutinin syndrome.
Hb	: Haemoglobin.
MCV	: Mean cell volume.
LDH	: Lactate dehydrogenase.
MCH	: Mean corpuscular haemoglobin.
MCHC	:Mean corpuscular haemoglobin
	concentration.
PRBC	: Packed red blood cell concentrate
AS	: Antibody screening.
AI	: Antibody identification.
bil	: Bilirubin
LFT	: Liver function tests.
FNAC	: Fine needle aspiration cytology.
MCL	: Mantle cell lymphoma.
ALPS	: Autoimmune lymphoproliferative syndromes.
DHTR	: Delayed haemolytic transfusion reactions.
HDFN	: Haemolytic disease of newborn.
BMRI	: Bone marrow responsiveness.
ARC	: Absolute reticulocyte count.
ES	: Evans syndrome.
NGS	: Next-generation sequencing.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

- 1. Barcellini W, Fattizzo B. The changing landscape of autoimmune hemolytic anemia. Front Immunol 2020;11:946.
- 2. Kaur P, Basu S, Kaur R, Kaur G. Immune hemolytic anemia: A report of two cases. J Lab Physicians 2009;1:22-4.
- 3. Fattizzo B, Zaninoni A, Gianelli U, Zanella A, Cortelezzi A, Kulasekararaj AG, *et al.* Prognostic impact of bone marrow fibrosis and dyserythropoietic in autoimmune hemolytic anemia. Am J Hematol 2018;93:E88–91. doi: 10.1002/ajh. 25020.
- 4. Fattizzo B, Barcellini W. Autoimmune cytopenias in chronic lymphocytic leukemia: Focus on molecular aspects. Front Oncol 2020;9:1435.
- 5. Park SH. Diagnosis, and treatment of autoimmune hemolytic anemia: Classic approach and recent advances. Blood Res 2016;51:69-71.
- 6. Hill QA, Hill A, Berentsen S. Defining autoimmune hemolytic anemia: A systematic review of the terminology used for diagnosis and treatment. Blood Adv 2019;3:1897–906.
- 7. Hill A, Hill QA. Autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2018;2018:382-9.
- 8. Adult values established by reference range studies performed by VCU Medical Centre Hematology Laboratory.
- 9. Chaudhary R, Das SS. Autoimmune hemolytic anemia: From lab to bedside. Asian J Transfus Sci 2014;8:5-12.
- 10. Pediatric Reference Intervals. 5th ed. AACC Press; 2005.
- 11. Takahashi T. Direct antiglobulin test-negative autoimmune hemolytic anemia. Acta Haematol 2018;140:18-9.
- 12. Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Dis Markers 2015;2015:635670.
- 13. Aladjidi N, Leverger G, Leblanc T, Picat MQ, Michel G, Bertrand Y, *et al.* New insights into childhood autoimmune hemolytic anemia: A French national observational study of 265 children. Haematologica 2011;96:655-63.
- 14. Russo R, Gambale A, Langella C, Andolfo I, Unal S, Iolascon A. Retrospective cohort study of 205 cases with congenital dyserythropoietic anemia type II: Definition of the clinical and molecular spectrum and identification of new diagnostic scores. Am J Hematol 2014;89:E169-75.